| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Departments of Radiological Sciences (W.B.P.), Neurology (A.L., P.N., T.F.C.), and Pathology and Laboratory Medicine (P.M.), David Geffen School of Medicine at UCLA, Los Angeles, CA.
Address correspondence and reprint requests to Dr. Whitney B. Pope, Department of Radiological Sciences, David Geffen School of Medicine at UCLA Medical Center, 10833 Le Conte Avenue, BL-428/CHS, Los Angeles, CA 90095-1721; e-mail: wpope{at}mednet.ucla.edu
Patients with recurrent gliomas (n = 14) were treated with bevacizumab and carboplatin, cpt-11, or etoposide. Follow-up MRI scans were obtained 2 to 6 weeks after initiation of treatment. Contrast-enhancing tumor shrank in 7 patients, with reductions evident in as little as 2 weeks after initiation of therapy. Treatment seemed more effective for heterogeneously enhancing tumor compared with solidly enhancing tumor.
Disclosure: The authors report no conflicts of interest.
Received October 4, 2005. Accepted in final form January 13, 2006.
This article has been cited by other articles:
|
|
 |
|
  F. M. Iwamoto, L. E. Abrey, K. Beal, P. H. Gutin, M. K. Rosenblum, V. E. Reuter, L. M. DeAngelis, and A. B. Lassman Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma Neurology, October 13, 2009; 73(15): 1200 - 1206. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. B. Pope, H. J. Kim, J. Huo, J. Alger, M. S. Brown, D. Gjertson, V. Sai, J. R. Young, L. Tekchandani, T. Cloughesy, et al. Recurrent Glioblastoma Multiforme: ADC Histogram Analysis Predicts Response to Bevacizumab Treatment Radiology, July 1, 2009; 252(1): 182 - 189. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Chi, A. G. Sorensen, R. K. Jain, and T. T. Batchelor Angiogenesis as a Therapeutic Target in Malignant Gliomas Oncologist, June 1, 2009; 14(6): 621 - 636. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. S. Kamoun, C. D. Ley, C. T. Farrar, A. M. Duyverman, J. Lahdenranta, D. A. Lacorre, T. T. Batchelor, E. di Tomaso, D. G. Duda, L. L. Munn, et al. Edema Control by Cediranib, a Vascular Endothelial Growth Factor Receptor-Targeted Kinase Inhibitor, Prolongs Survival Despite Persistent Brain Tumor Growth in Mice J. Clin. Oncol., May 20, 2009; 27(15): 2542 - 2552. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. L. Nghiemphu, W. Liu, Y. Lee, T. Than, C. Graham, A. Lai, R. M. Green, W. B. Pope, L. M. Liau, P. S. Mischel, et al. Bevacizumab and chemotherapy for recurrent glioblastoma: A single-institution experience Neurology, April 7, 2009; 72(14): 1217 - 1222. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Chamberlain, M. M. Mrugala, A. D. Norden, G. S. Young, and P. Y. Wen BEVACIZUMAB FOR RECURRENT MALIGNANT GLIOMAS: EFFICACY, TOXICITY, AND PATTERNS OF RECURRENCE Neurology, February 24, 2009; 72(8): 772 - 774. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Jahnke, L. L. Muldoon, C. G. Varallyay, S. J. Lewin, D. F. Kraemer, and E. A. Neuwelt Bevacizumab and carboplatin increase survival and asymptomatic tumor volume in a glioma model Neuro-oncol, January 1, 2009; 11(2): 142 - 150. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. C. Quant, A. D. Norden, J. Drappatz, A. Muzikansky, L. Doherty, D. LaFrankie, A. Ciampa, S. Kesari, and P. Y. Wen Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab Neuro-oncol, January 1, 2009; 11(5): 550 - 555. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. B. Pope, J. H. Chen, J. Dong, M. R. J. Carlson, A. Perlina, T. F. Cloughesy, L. M. Liau, P. S. Mischel, P. Nghiemphu, A. Lai, et al. Relationship between Gene Expression and Enhancement in Glioblastoma Multiforme: Exploratory DNA Microarray Analysis Radiology, October 1, 2008; 249(1): 268 - 277. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. W Buie and J. Valgus Bevacizumab: A Treatment Option for Recurrent Glioblastoma Multiforme Ann. Pharmacother., October 1, 2008; 42(10): 1486 - 1490. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Idbaih, F. Ducray, M. Sierra Del Rio, K. Hoang-Xuan, and J.-Y. Delattre Therapeutic Application of Noncytotoxic Molecular Targeted Therapy in Gliomas: Growth Factor Receptors and Angiogenesis Inhibitors Oncologist, September 1, 2008; 13(9): 978 - 992. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. D. Norden, G. S. Young, K. Setayesh, A. Muzikansky, R. Klufas, G. L. Ross, A. S. Ciampa, L. G. Ebbeling, B. Levy, J. Drappatz, et al. Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence Neurology, March 4, 2008; 70(10): 779 - 787. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.W. Henson, S. Ulmer, and G.J. Harris Brain Tumor Imaging in Clinical Trials AJNR Am. J. Neuroradiol., March 1, 2008; 29(3): 419 - 424. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Chamberlain Bevacizumab Plus Irinotecan in Recurrent Glioblastoma J. Clin. Oncol., February 20, 2008; 26(6): 1012 - 1013. [Full Text] [PDF]
|
|
|
|
|
|
S. Sathornsumetee, Y. Cao, J. E. Marcello, J. E. Herndon II, R. E. McLendon, A. Desjardins, H. S. Friedman, M. W. Dewhirst, J. J. Vredenburgh, and J. N. Rich Tumor Angiogenic and Hypoxic Profiles Predict Radiographic Response and Survival in Malignant Astrocytoma Patients Treated With Bevacizumab and Irinotecan J. Clin. Oncol., January 10, 2008; 26(2): 271 - 278. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Nghiemphu, R. M. Green, W. B. Pope, A. Lai, and T. F. Cloughesy Safety of anticoagulation use and bevacizumab in patients with glioma Neuro-oncol, January 1, 2008; 10(3): 355 - 360. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Gomez-Manzano, J. Holash, J. Fueyo, J. Xu, C. A. Conrad, K. D. Aldape, J. F. de Groot, B. N. Bekele, and W. K. A. Yung VEGF Trap induces antiglioma effect at different stages of disease Neuro-oncol, January 1, 2008; 10(6): 940 - 945. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Chen, S. Delaloye, D. H.S. Silverman, C. Geist, J. Czernin, J. Sayre, N. Satyamurthy, W. Pope, A. Lai, M. E. Phelps, et al. Predicting Treatment Response of Malignant Gliomas to Bevacizumab and Irinotecan by Imaging Proliferation With [18F] Fluorothymidine Positron Emission Tomography: A Pilot Study J. Clin. Oncol., October 20, 2007; 25(30): 4714 - 4721. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. G. Duda, R. K. Jain, and C. G. Willett Antiangiogenics: The Potential Role of Integrating This Novel Treatment Modality With Chemoradiation for Solid Cancers J. Clin. Oncol., September 10, 2007; 25(26): 4033 - 4042. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R.J. Carlson, W. B. Pope, S. Horvath, J. G. Braunstein, P. Nghiemphu, C.-L. Tso, I. Mellinghoff, A. Lai, L. M. Liau, P. S. Mischel, et al. Relationship between Survival and Edema in Malignant Gliomas: Role of Vascular Endothelial Growth Factor and Neuronal Pentraxin 2 Clin. Cancer Res., May 1, 2007; 13(9): 2592 - 2598. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Chamberlain, W. B. Pope, and T. Cloughesy MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy Neurology, December 12, 2006; 67(11): 2089 - 2089. [Full Text] [PDF]
|
|
Read all Correspondence
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
